← Back to Search

18F-DCFPyL for Prostate Cancer (PROSPYL Trial)

Phase 2

Waitlist Available

Led By Gholam Berenji, M.D.

Research Sponsored by VA Greater Los Angeles Healthcare System

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

PROSPYL Trial Summary

This trial is to study whether a PET scan using 18F-DCFPyL affects the clinical management plan in Veterans with cancer.

Eligible Conditions

Prostate Cancer

PROSPYL Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

PRIMARY OBJECTIVES: I. To determine the impact of 18F-DCFPyL PET/CT on initial and subsequent treatment strategies of patients with prostate cancer.

Side effects data

From 2019 Phase 3 trial • 208 Patients • NCT03739684

Headache

Fatigue

Hypertension

100%

80%

60%

40%

20%

Study treatment Arm

18F-DCFPyL Injection

PROSPYL Trial Design

1Treatment groups

Experimental Treatment

Group I: PEt/CT armExperimental Treatment1 Intervention

Subjects receive a PET/CT scan.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Piflufolastat F 18

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

VA Greater Los Angeles Healthcare SystemLead Sponsor

51 Previous Clinical Trials

8,169 Total Patients Enrolled

2 Trials studying Prostate Cancer

117 Patients Enrolled for Prostate Cancer

Gholam Berenji, M.D.Principal InvestigatorAttending Physiscian

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How has 18F-DCFPyL been found to be effective in previous treatments?

"18F-DCFPyL is a medication used to lower serum prostate specific antigen (psa) levels. Other potential uses for this treatment include imaging for metastasis, positron emission tomography, and recurrent prostate cancer."

Answered by AI

Has 18F-DCFPyL been accepted by the FDA?

"Because this is a Phase 2 trial, there is some data supporting safety but none supporting efficacy, so our team at Power estimated the safety of 18F-DCFPyL to be a 2."

Answered by AI

Can you name some other times 18F-DCFPyL has been used in a medical trial?

"There are a total of 19 clinical trials that are investigating 18F-DCFPyL and 0 of those are in Phase 3. The majority of these research studies are being conducted in Baltimore, Maryland; however, there are 28 total locations running these trials."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

2020. "18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04390880.